biotech earnings August 2026
RenovoRx Hits 52-Week High as Revenue and Trial News Align
RenovoRx spent August checking boxes most microcap biotechs take years to check. A pivotal trial finished enrolling. Quarterly revenue kept climbing. A Nasdaq compliance problem got resolved. By month’s end, the stock was sitting at a 52-week high. RenovoRx Hits 52-Week High as Revenue Growth and Trial Enrollment Both Deliver RenovoRx (Nasdaq: RNXT) shares rose…
OmniAb Jumps 13% on Eli Lilly Ion Channel Collaboration
OmniAb landed a partner with deep pockets on Monday. Acurx Pharmaceuticals landed something smaller but just as telling: a brand name regulators are willing to put on a drug label. Neither event is an approval. Both moved the stock like one. OmniAb Jumps 13% on Eli Lilly Collaboration Worth Up to $370 Million OmniAb (Nasdaq:…
Faeth Therapeutics Jumps 18% as Cash Grows to $186 Million
Faeth Therapeutics and Veru posted double-digit stock gains on the same Monday, for reasons that had nothing to do with each other. Faeth used its quarterly numbers to show it is sitting on nine times the cash it had six months ago. Veru used its own earnings call to confirm a trial enrolled faster than…
